Factory high quality Serratiopeptidase customized

Superiority:

37312-62-2 - Names and Identifiers

Name	Serratiopeptidase
Synonyms	dasen SERRATIOPEPTIDASE Serratiopeptidase SerratiopeptidaseSerrapeptase serratiaextracellularproteinase proteinase,serratiaextracellular
CAS	37312-62-2
EINECS	253-457-5

37312-62-2 - Physico-chemical Properties

Molecular Formula

ICl

Use

Serrapeptidase was found to have the ability of protein dissolution, which can inhibit the inflammatory substances, and is often used as a phlegm and pus medicine. At the same time, serrapeptidase also promotes the regeneration of cells and promotes the healing of wounds, when used with antibiotics, there is a synergistic effect to improve the antibacterial effect of antibiotics. So it is a good choice for traumatic drugs.

37312-62-2 - Pharmacological action and clinical evaluation of serrapeptidase

from Wanfang

Author:

pan , he Lixian

Abstract:

serrapeptidase is a potent expectorant, anti-inflammatory and detumescence multiple role of enzyme preparations, can quickly break down denatured protein, bradykinin and cellulose clots, the pus, sputum, blood clots and other liquefaction thinning, easy drainage, accelerate wound purification, promote granulation tissue new life. Widely used in clinical phlegm and swelling. This article reviews the pharmacological action and clinical application of serrapeptidase.

Key words:

respiratory disease serrapeptidase Anti-inflammatory detumescence expectorant

DOI:

CNKI:SUN:XYYL.0.2008-08-020

cited:

20

year:

2008

Last Update：2024-01-02 23:10:35

37312-62-2 - Serrapeptidase preparation

from Palm Bridge research

patent type:

invention patent

Application (patent) number:

CN201711453142.3

application date:

20171228

Public/Announcement Number:

CN108078963A

Public/announcement date:

20180529

applicant (patent):

Zhengzhou Assisted Living Science and Technology Co., Ltd.

inventor:

no announcement inventor

National and provincial code:

CN410102

Abstract:

A serrapeptidase preparation, including, but not limited to, inhalation powder aerosol, Inhalation Aerosol. Said serrapeptidase inhalation preparation, wherein the serrapeptidase is micronized, has a particle size distribution in the range of 1100 μm, preferably 350 μm. The serrapeptidase preparation is administered by inhalation, and is used for inflammation, edema and expectoration difficulty caused by various respiratory diseases.

objective to study the clinical application value of Budesonide Nasal Spray combined with Serrapeptase Enteric-coated Tablets in the treatment of allergic rhinitis. Methods from October 2007 to October 2010, 150 patients with allergic rhinitis were diagnosed in the Department of Otolaryngology in our hospital. The patients were randomly divided into budesonide group, serrapeptidase group and combination group, 50 cases in each group. Budesonide group was treated with 1 spray of drug from Budesonide Nasal Spray pair of nasal spray on each side every morning and evening for 4 weeks; Serrapeptidase group was treated with oral administration of Serrapeptase Enteric-coated Tablets 10 mg, 3 times/d, for 7 days; in the combination group, Budesonide Nasal Spray and Serrapeptase Enteric-coated Tablets were used at the same dose and duration as in the previous two groups. The disease symptoms, signs scores and adverse drug events were recorded before and after treatment, and the curative effects of the three groups were compared. Results after treatment, the combined drug group IL-9,IL-13 content was significantly lower than that of budesonide group and serrapeptidase group [(17.4±5.9) ng/L vs (48.4±9.1)ng/L,(46.3±7.9) ng/L; (200.9±42.8) ng/L (310.4±68.4) ng/L,(268.9±61.2) ng/L, the difference was statistically significant (F = 22.46, comparison of total effective rate of three groups, budesonide group [0.05 (31/50)] and serrapeptidase group [62% (30/50)] compared with the combination group [80% (40/50)], the differences were statistically significant (x2 = 8.73,7.89, all P<0.05), there was no significant difference between budesonide group and serrapeptidase group (x2 = 0.21,P>0.05). Conclusion The combination of Budesonide Nasal Spray and serrapeptidase tablets has good stability and good tolerance, which can control the onset of allergic rhinitis, improve the quality of life and improve the prognosis, it is worthy of clinical application and promotion.